Skip to content
Search AI Powered

Latest Stories

Will My Insurance Cover Psychedelic-Assisted Therapy? 

Key Takeaways:
- The American Medical Association (AMA) recently approved insurance billing codes for psychedelic therapy.
- The approval does not mean insurance companies will provide coverage for psychedelic therapy.
- DEA de-scheduling coupled with Food and Drug Administration (FDA) approval of psychedelics will be key for insurance companies to consider reimbursement.

Will Insurance Cover Psychedelic-Assisted Therapy?
Will Insurance Cover Psychedelic-Assisted Therapy?

The American Medical Association (AMA) has taken a significant step forward for psychedelic therapy by approving Current Procedural Technology (CPT) III codes for these treatments. The move has sparked hope among advocates and experts that insurance coverage for psychedelic-assisted therapy is on the horizon. However, this approval is only one piece of the puzzle, and there are several hurdles to overcome before insurance providers will consider reimbursing patients for these treatments.

CPT codes are essential in the healthcare industry as they allow healthcare providers to track and bill for various procedures and services. The newly approved CPT III codes for psychedelic therapies will become effective in January 2024. 


However, it is crucial to note that these codes do not equal coverage. On its website, the AMA states that the “inclusion of a descriptor and its associated code number does not represent endorsement by the AMA of any particular diagnostic or therapeutic procedure or service. Inclusion or exclusion of a procedure or service does not imply any health insurance coverage or reimbursement policy.”

Enthea, is one of the first providers of insurance plans for psychedelic healthcare, with plans that currently cover ketamine-assisted therapy; MDMA- and psilocybin-assisted therapies will be added as they become FDA-approved in the next several years.

“Through the creation of the country’s first psychedelic healthcare provider network, Enthea is taking a big step in creating access to these new, evidence-based healing options,” said Sherry Rais, CEO and Co-Founder of Enthea. “And as a workplace benefit, this treatment becomes affordable. Next year, most employers across the U.S will be able to offer these innovative treatments, covered under insurance, for the first time.”

Ms. Rais also acknowledges that most traditional insurance providers will likely require more concrete evidence before committing to reimbursement.

The legal status of psychedelics plays a crucial role in insurance coverage decisions. While some states have legalized or decriminalized certain psychedelic substances for specific mental health conditions, the Food and Drug Administration (FDA) has not yet approved psychedelics for therapeutic use. FDA approval, along with DEA rescheduling, is vital for insurance companies to consider covering psychedelic therapy.

Several companies and organizations, including COMPASS Pathways, MAPS Public Benefit Corporation, and Numinus, are actively working to pave the way for potential insurance coverage of MDMA and psilocybin. Despite the progress, there are still significant costs associated with psychedelic therapy. 

The substances themselves are not expensive, but the long-term talk therapy needed after a psychedelic-assisted session can be costly. Integration, the process of incorporating insights from the psychedelic experience into daily life, involves activities like journaling, mindfulness practices, and continuing talk therapy.

Insurance coverage not only reduces financial burdens for patients but also provides reassurance about the safety and viability of psychedelic therapy. According to Payton Nyquvest, CEO of Numinus, insurance coverage will be essential for increasing access to these treatments. It will also encourage more people to consider psychedelic therapy as a viable option for mental health care.

The University of California Berkeley Center for the Science of Psychedelics conducted a survey revealing that more than half of respondents support FDA approval of psychedelics. However, insurance coverage for psychedelic therapy is not yet widespread. Even FDA-approved treatments like ketamine, a Schedule III controlled substance, are not consistently covered by insurance companies.

The process of integrating psychedelic-assisted therapy into the mainstream healthcare system is in its early stages. The American Psychedelic Practitioners Association (APPA) is working on accrediting practitioners in the field to ensure legitimacy and safety. However, it will take time and effort to gain acceptance and certification in the clinical world.

While the approval of CPT codes is a positive step forward, there is still a long road ahead before insurance coverage for psychedelic-assisted therapy becomes a reality. Full FDA approval and DEA rescheduling are paramount, along with peer-reviewed evidence from clinical trials and proper practitioner training. Insurance companies will need convincing data on safety, efficacy, and cost-effectiveness before providing comprehensive coverage for these groundbreaking treatments.

As the field of psychedelic therapy continues to evolve, patients, providers, and advocates remain hopeful that insurance coverage will eventually be available, making these transformative treatments more accessible to those in need. However, until the necessary steps are taken, patients will need to explore alternative financing options to access this potentially life-changing therapy.

More For You

Magic mushrooms come in more strains than you might realize.
Magic mushrooms come in more strains than you might realize.

Magic Mushrooms: An Overview of Different Psilocybin Strains and Effects

Like cannabis, magic mushrooms exist as strains and species. These terms are used to describe the physical or chemical characteristics of the plants. While they are often used interchangeably, strains and species are not the same. 

Psilocybin mushrooms contain psilocybin, psilocin, and baeocystin. These compounds interact with the serotonin receptors to control biological and neurological processes like sleep, anxiety, cognition, appetite, nausea, learning, memory, and thermoregulation. 

Keep ReadingShow less
Getting you ready for your first magic mushroom trip.
Getting you ready for your first magic mushroom trip.

How Long Do Shrooms Last? How Do You Eat Them? A Guide To Your First Magic Mushroom Trip

In 2022, general interest in magic mushrooms has spiked to unprecedented levels not seen since the 1960s. Thanks to research showing promising results for patients, lawmakers a handful of states and cities already have or are considering loosening psilocybin restrictions.

A few states such as Oregon have fully legalized psilocybin treatment for all adult patients, while others want to limit it to veterans or others with PTSD.

Keep ReadingShow less
Tripping with your phone? Maybe.
Tripping with your phone? Maybe.

These Apps Could Help You Experience A Trip Without Tripping

Psychedelic exploration is seeing its first renaissance since the mid-century, but while the substances seem to have a largely positive effect on a person’s mental and physical wellbeing, the idea of “tripping” might still sound terrifying to a number of people. 

Thankfully, there’s an app for that – i.e., a number of apps designed to allow people to experience something similar to a psychedelic journey without actually indulging in any psychedelics.  

Keep ReadingShow less
Dosage levels can lead to completely different experiences with psilocybin.
Dosage levels can lead to completely different experiences with psilocybin.
Photo by Artur Kornakov on Unsplash

Psilocybin 101: Macrodosing vs. Microdosing

Mental health experts are shifting more attention to the world of psychedelics: specifically psilocybin, a.k.a. “magic mushrooms.” 

Cultures around the world have been utilizing the spiritual fungi for centuries, and as today’s society challenges what so many have been ingrained to view as “wrong” for decades, more people are experimenting with shrooms and exploring the positive effects they seem to have on the human psyche. 

Keep ReadingShow less
Albino A+ shrooms are not for beginners.
Albino A+ shrooms are not for beginners.

Albino A+ Magic Mushrooms: A Helpful Guide

Albino A+ or AA+ mushroom strains represent a large group of psychoactive mushrooms (Psilocybe cubensis) or magic mushrooms. While Albino A+ are classified as potent psilocybin strains, they contain a lower concentration of psilocybin, making them less potent than Penis Envy shrooms

One can identify this species Albino mushroom strains appear cream-colored to white with a bluish tint visible when the fruiting body is bruised or crushed. The strains are popular thanks to their high potency, availability, and large flushes. 

Keep ReadingShow less